Phase III COMPASS study of Xarelto stopping early for 'overwhelming efficacy'

9 February 2017

The Phase III trial COMPASS evaluating the efficacy and safety of Xarelto (rivaroxaban) for the prevention of major adverse cardiac events (MACE) including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) has met its primary endpoint ahead of time.

Blood thinner Xarelto was discovered by Germany’s Bayer (BAYN: DE) and is marketed in the USA with its cooperation partner Janssen Research & Development, a unit of US healthcare giant Johnson & Johnson (NYSE: JNJ). The drug generated third-quarter 2016 sales of 571 million euros ($611.5 million) for Bayer. According to J&J’s recently-reported financials, Xarelto had sales of $2.29 billion in 2016.

Bayer’s shares gained 2.23% to 105.35 euros in late-morning trading today.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK